A “Whole New World” of Lymphatic System Discovered

The Discovery

Recent findings at the University of Finland and UVA School of Medicine have overturned 300 years of accepted anatomical fact. Until recent years, the scientific community believed that the lymphatic system — which functions in the body to remove waste and toxins — did not extend into the human brain.

Then came Kari Alitalo. Kari desired a better map of the lymphatic vessels, so three years ago he dosed the lymph cells of mice with a glowing jellyfish gene. At the end of the experiment, he was shocked to see that the mice’s heads were glowing. To be certain his results were correct, he repeated the experiment. His repeat showed exactly the same phenomenon.

As it turns out, Kari had discovered what he termed to be the glymphatic system — the division of the lymphatic system that exists as “glia” cells in the brain.

The Glymphatic System

As it turns out, the glymphatic system may have major implications for degenerative diseases. It’s possible that Alzheimer’s, Huntington’s, and Parkinson’s diseases could be effected by dysfunction in the glymphatic system. A dysfunctional lymphatic system can lead to a buildup of toxins and waste in the body — and a dysfunctional glymphatic system may lead to a buildup of toxins in the brain.

Early studies at Yale and Oregon Health & Science University suggest that a functioning glymphatic system is essential to a healthy brain. Harvard has shown that glymphatic flow is decreased right before a migraine. Research has also shown that the glymphatic system works best when we are asleep, and that sleeping on your side is better than sleeping on your stomach or back.

 

It’s clear that this revolutionary anatomical discovery will have major impact for clinical therapies for all kinds of neurodegenerative diseases. Read the full article from the Washington Post here, and make sure to subscribe to our blog for the latest news and events across the biotech world.

Alzheimer’s PET Scan – US National Institute on Aging, Alzheimer’s Disease Education and Referral Center

Barbara Osband, Chairwoman and CEO, Announces Addition of Dr Thomas Burnell to Cambridge Biomedical Advisory Board

Cambridge Biomedical announces the addition of Dr. Thomas W. Burnell to the Cambridge Biomedical Advisory Board.

 

“We welcome the addition of Dr. Burnell to our Advisory Board” said Barbara Osband, Chairwoman and CEO “ his extensive experience in the CRO and diagnostic laboratory market will greatly assist as we continue to expand or capabilities and client base”

 

Dr Burnell

 

Dr. Burnell, is an Operating Partner with Ampersand Capital Partners.  In this capacity, he has served as President and CEO of Nutramed, Inc., and its successor corporation, Elite One Source Nutritional Services, Inc.  Currently, he serves as Exec Chair of Elite One and formerly Accuratus Lab Services, Inc. Prior to this, he served as President and Chief Executive Officer of Viracor-IBT Laboratories, Inc.  He has served as President, Chief Executive Officer and Chairman of the Board of the The Nebraska Heart Institute, P.C. and Nebraska Heart Hospital, LLC. Dr. Burnell previously served as the Chief Executive Officer and Vice Chairman for Eurofins Scientific, Inc.  Dr. Burnell has served as a Director of numerous privately-held corporations and non-profit philanthropic organizations.  He has more than 25 years of experience in healthcare, biotechnology, laboratory sciences, manufacturing and international business development. Dr. Burnell received his BS and Master’s degrees from the University of Nebraska and holds a PhD in Nutrition with emphasis in Statistics and Biochemistry from the University of Kentucky.

 

 

 

About Cambridge Biomedical

 

Cambridge Biomedical, based in Boston, Massachusetts, supports sponsors by developing customized assays for small and large molecules, biomarkers, and other critical analytes, along with validation and sample testing in our CLIA certified and CAP accredited, GLP/GCLP compliant facilities,

 

The Company has extensive expertise in technology transfer, assay development, optimization and validation. It also offers specific services in analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis, and testing services in support of clinical trial and drug or device development.

 

Our personalized project methodology, along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensures we meet our client’s product development timelines.

Development of novel Fluorescence-activated cell sorting (FACS) and Immunoprecipitation (IP)/Western-Blot assays to characterize antibody therapies

Dr Ralf Geiben Lynn, Senior Research Scientist at Cambridge biomedical has authored our latest whitepaper on the Development of novel Fluorescence-activated cell sorting (FACS) and Immunoprecipitation (IP)/Western-Blot assays to characterize antibody therapies.

 

Background:

Biotech industry is in a boom, and we at Cambridge Biomedical are proud that we can contribute to it. The arrival of new antibody therapies feels like a fresh ocean breeze at Biarritz, France, which we can still feel here in Boston. In our role as a bioanalytical assay CRO, we are involved in the development of novel therapeutic antibodies that show examples of how the industry creates sustainable growth, which drive this boom.

 

There are multiple new antibodies that boost the immune system and that are part of novel therapeutic interventions. Some of these antibodies enhance T-cell immune responses: Pembrolizumab (Keytruda, MK-3475, Merck) is approved to treat metastatic melanoma. New applications may include lung cancer and mesothelioma. Nivolumab (Opdivo, Bristol Myer Squibb) reduced non-small cell lung cancer, melanoma, renal-cell cancer in a clinical trial. Pidilizumab (CT-OII, Cure Tech) MPDL328OA (Roche) and BMS936559 (Bristol Myers Squibb) are also tested for other novel applications.

 

Click here to read the complete white paper.

Cambridge Biomedical Spring 2016 Newsletter

Cambridge Biomedical continues its expansion and we are seeking Senior Scientists and Research Associates to join our dynamic team. If you know of anyone in the Boston area who would be interested in joining our team please let us know or visit our website.

Did you know that Cambridge Biomedical also provides logistics and project management support for your trials? We have extensive experience in working with clients and multiple partners to ensure that your trials run smoothly. Our range of services includes development and manufacturing of kits, sourcing of material, co-ordination with external labs and preparation of consolidated reports, all under GLP/GCLP regulatory guidance. If you would like to discuss these services in more detail please contact us and we will be delighted to assist you.

Click here to view the full newsletter

Cambridge Biomedical announces that Tim Smith has been appointed Chief Financial Officer, effective Feb 1st, 2016.

Cambridge Biomedical announces that Tim Smith has been appointed Chief Financial Officer reporting to Brad Yount, President and Chief Operating Officer, effective Feb 1st, 2016.

“Tim has extensive experience in bringing operational improvements and financial acumen to developing companies. I have worked with Tim in previous organizations and have tremendous confidence that he will help to further strengthen Cambridge Biomedical’s capabilities” said Brad Yount, President and Chief Operating Officer Officer.

Smith will assume responsibility for financial operations in Cambridge Biomedical and is focused on improving operational efficiencies within the company as it positions itself for continuing double-digit growth.

“Cambridge Biomedical’s strength in bioanalytical assays and diagnostic testing is well known in the industry” Smith commented “and I am excited by this opportunity to help develop the infrastructure within the company with its team of highly experienced staff through its next phase of growth”

Prior to this appointment, Smith was responsible for the the financial operations of several different companies in Maine, Massachusetts, New Jersey and Europe. Mr. Smith received a BS in Management from Susquehanna University and an MBA from Lehigh University and is also a certified CPA.

About Cambridge Biomedical

Cambridge Biomedical, based in Boston, Massachusetts, supports sponsors by developing customized assays for small and large molecules, biomarkers, and other critical analytes, along with validation and sample testing in our CLIA certified and CAP accredited, GLP/GCLP compliant facilities,

The Company has extensive expertise in technology transfer, assay development, optimization and validation. It also offers specific services in analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis, and testing services in support of clinical trial and drug or device development.

Our personalized project methodology, along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensures we meet our client’s product development timelines.

Cambridge Biomedical Exhibiting at MassBio CRO/CMO Symposium

We will be exhibiting at the Massachusetts Biotech Council CRO/CMO Symposium on Friday 13th November.

This event will be held at the Renaissance Boston Waterfront Hotel, 606 Congress Street, Boston, MA 02210  and is now in its fourth year, the MassBio CRO/CMO Symposium shines a spotlight on the strength and success of the CRO and CMO communities in the Commonwealth.

The Symposium draws more than 300 attendees to discuss and evaluate the best alternatives that have evolved in shortening time to market. A series of case studies, interactive panel discussions, and networking sessions provide ample time to explore the various techniques and approaches being used by both virtual and established companies.

Click here to register